Close Menu

commercialization agreement

The companies will form a joint venture for Todos' cancer tests with Care GB owning 67 percent and Todos owning 33 percent of the new venture.

IncellDx has been developing a test for cytokine storm-related cytokines, which it said are elevated in COVID-19 patients who experience long-term symptoms.

HTG will work directly with biopharma customers to build companion diagnostic development programs, with potential tests developed using either a Thermo Fisher Scientific or Illumina platform.

According to the agreement, Access Bio must sell at least 2 million tests by Sept. 30, 2021, to keep its exclusive rights in North America.

OpGen will promote the system for the enrichment of circulating endothelial cells from whole blood, which could be useful for COVID-19 research.

The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.

Genetron's S5 sequencer is based on Thermo Fisher's Ion GeneStudio S5 instrument and is cleared for clinical use by China's NMPA.

The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.

The firm has characterized the new product as a way to seize an opportunity, rather than a shift from its ID-AST focus.

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

Pages